Entrada Therapeutics, Inc.
TRDA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001689375
In the last 90 days, Entrada Therapeutics, Inc. insiders filed 0 open-market purchases and 7 sales; 128 institutions reported holding it in 13F filings for Q2 2026, worth $214.4M in total; no superinvestor holds it.
Q2 2024 vs. Q1 2024
How the institutions holding Entrada Therapeutics, Inc. changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Of which not filed for Q2 2024 | Q2 2024 | Change |
|---|---|---|---|---|
| Holders | 77 | 2 | 84 | +9 |
| Shares | 26.0M | 33.4K | 29.7M | +3.70M (+14.2%) |
| Value | $368.8M | $473.2K | $423.1M | +$54.8M (+14.9%) |
2 institutions that held it in Q1 2024 haven't filed for Q2 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (18)
Institutions that held Entrada Therapeutics, Inc. at the end of Q2 2024 but not at the end of Q1 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Janus Henderson Group PLC | 1,549,497 | $22.1M | 0.01% |
| Jacobs Levy Equity Management, Inc | 134,244 | $1.91M | 0.01% |
| Renaissance Technologies LLC | 44,600 | $635.5K | 0.00% |
| Jane Street Group, LLC | 26,754 | $381.2K | 0.00% |
| EntryPoint Capital, LLC | 23,992 | $341.9K | 0.16% |
| Gsa Capital Partners LLP | 21,293 | $303.0K | 0.02% |
| ExodusPoint Capital Management, LP | 15,524 | $221.0K | 0.00% |
| Ameriprise Financial Inc | 13,547 | $193.0K | 0.00% |
| Walleye Capital LLC | 13,323 | $189.9K | 0.00% |
| Corebridge Financial, Inc. | 13,284 | $189.3K | 0.00% |
| Cornerstone Investment Partners, LLC | 11,390 | $162.3K | 0.01% |
| Mirae Asset Global ETFs Holdings Ltd. | 11,389 | $162.3K | 0.00% |
| UBS Asset Management Americas Inc | 10,512 | $149.8K | 0.00% |
| Alliancebernstein L.P. | 10,220 | $145.6K | 0.00% |
| Public Employees Retirement System of Ohio | 8,600 | $122.5K | 0.00% |
| Advisor Group Holdings, Inc. | 398 | $5.67K | 0.00% |
| SRS Capital Advisors, Inc. | 45 | $642 | 0.00% |
| C M Bidwell & Associates Ltd | 29 | $413 | 0.00% |
Sold out (9)
Institutions that held Entrada Therapeutics, Inc. at the end of Q1 2024 and filed for Q2 2024 without it.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Winton Group Ltd | 32,555 | $461.3K |
| Natixis | 31,186 | $432.9K |
| New York Life Investment Management LLC | 25,914 | $367.2K |
| Harbor Capital Advisors, Inc. | 14,543 | $206.0K |
| American International Group, Inc. | 10,546 | $149.4K |
| SG Americas Securities, LLC | 7,687 | $109.0K |
| New York State Teachers Retirement System | 1,915 | $27.0K |
| Metropolitan Life Insurance Co | 1,212 | $17.2K |
| Nelson, Van Denburg & Campbell Wealth Management Group, LLC | 4 | $56 |
Not filed for Q2 2024 yet (2)
Institutions that held Entrada Therapeutics, Inc. at the end of Q1 2024 and haven't filed a 13F for Q2 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Oracle Alpha Inc. | 17,341 | $245.7K |
| Credit Suisse AG | 16,052 | $227.5K |